Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Inclusion Criteria: * Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer * Recurrent ovarian cancer disease * Signs for progression either measurable disease according to RECIST or CA 125 increase according the GCIG-criteria or clinical symptoms of tumor progression according to RECIST * Radiologically and cytologically confirmed malignant ascites possible to puncture * Life expectancy ≥ 12 weeks * Age ≥ 18 years * ECOG performance status at least 1 * No prior operation or, in case of prior operation, the patient must be recovered therefrom. The operation must be performed at least 4 weeks prior to start of study drug * Capable of understanding the purposes and risks of the study, willing and able to participate in the study, and written informed consent * Non-childbearing potential or negative pregnancy test Exclusion Criteria: * known brain metastases * Concomitant cancer, chemo- or radiotherapy (except for local radiation therapy for bone marrow metastases) * Any investigational product within 2 weeks prior to first administration of catumaxomab * In cases of previous exposure to investigational product, cancer-, chemo-, immune- or radiotherapy (except for local radiation therapy for bone marrow metastasis): not sufficiently recovered from previous treatment (toxicity present) based on adequate laboratory values and general status according to other in-/exclusion criteria (i.e. this might be less than 1 or 2 weeks after a weekly or bi-weekly scheduled previous therapy regimen) * Patients must not have been exposed to nitrosoureas or mitomycin C within 6 weeks prior the first infusion of catumaxomab * Abnormal organ or bone marrow function * Use of immune-suppressive agents for the past 4 weeks prior to first administration of catumaxomab. For regular use of systemic corticosteroids patients should only be included after stepwise discontinuation to be free of steroids for a minimum of 5 days prior to study entry * Any known active and chronic infection * Known HIV infection and / or hepatitis B virus or hepatitis C virus * Any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator * Known or suspected hypersensitivity to catumaxomab and its analogues in general or to murine proteins (from rat or mouse) * Known or suspected hypersensitivity to PLD, topotecan, paclitaxel, gemcitabine or their excipients. * Patients with congestive heart failure New York Heart Association (NYHA) Class III and IV. Cardiac arrhythmias (except atrioventricular block type I and II, atrial fibrillation/flutter bundle brunch block)or other signs and symptoms of relevant cardiovascular disease * Body mass index (BMI) \< 17 (assessment after ascites drainage) * Inadequate respiratory function in the opinion of the investigator * Presence of complete bowel obstruction * Patients with substance abuse, medical or psychological or social conditions which the investigator believes would preclude compliance with the study requirements. * Unwilling or unable to follow protocol requirements * Participation in another clinical study with experimental therapy within 14 days before start of treatment * Legal incapacity or limited legal capacity * Subjects housed in an institution on official or legal orders * Pregnancy or lactation period